Cerebral venous thrombosis (CVT) presenting in the context of vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious complication that requires expert multidisciplinary management distinct from standard CVT care.
Clinical scenario: CVT occurring after an adenovirus-based SARS-CoV-2 vaccine in a patient with thrombocytopenia and platelet factor 4 antibodies. VITT and CVT may occur days to a few weeks after vaccination, typically presenting with new-onset headaches and thrombocytopenia. Laboratory testing for platelet factor 4 antibodies is recommended in all suspected cases. Expert hematology and multidisciplinary team involvement is essential.
Management requires avoidance of heparin products. An alternative anticoagulation strategy is used, combined with immunomodulatory therapy. Platelet transfusions are not recommended in this setting.
Treatment goal: Full platelet count recovery.
The complete sequenced regimen — including agent selection, transitions, and additional therapies — is available in the full protocol.
DOI: 10.1161/STR.0000000000000456
In cases of suspected VITT, laboratory testing for platelet factor 4 antibodies is recommended.
VITT and CVT may occur (rarely) days or a few weeks after an individual receives adenovirus-based SARS-CoV-2 vaccines, usually presenting with new onset of headaches and thrombocytopenia; it requires the expert management of a hematologist and multidisciplinary team.
Despite the lack of evidence, given the similarity to autoimmune heparin-induced thrombocytopenia, avoidance of heparin products, intravenous immunoglobulin 1 g/kg body weight daily for 2 days, and administration of steroids have been advised.
Platelet transfusions are not recommended.
Nonheparin parenteral anticoagulants (argatroban, fondaparinux) are typically used first, with transition to an oral anticoagulant (ie, DOAC) once there is full platelet count recovery.
View source ↗